NCT00360607 - A Comparative Phase IV Study Evaluating Efficacy & Safety Of Magnex(Cefoperazone-Sulbactam) In Intraabdominal Infections | Biotech Hunter

Enrollment

307

Participants

Timeline

Start Date

July 31, 2004

Study Completion Date

April 30, 2005

Conditions

Infection

Interventions

DRUG

Magnex (Sulbactam Sodium/Cefoperazone Sodium 1:1) Pfizer Ltd.

DRUG

Fortum (Ceftazidime for injection USP) Glaxo Smith Kline Pharmaceuticals Limited

DRUG

Metrogyl (Metronidazole Injection IP) J.B.Chemicals & Pharmaceuticals Ltd.

DRUG

Mikacin (Amikacin Sulphate Injection IP) Aristo Pharmaceuticals Ltd.

Trial Locations (20)

302015

Pfizer Investigational Site, Jaipur

380016

Pfizer Investigational Site, Ahmedabad

682304

Pfizer Investigational Site, Kochi

380 009

Pfizer Investigational Site, Ahmedabad

380 052

Pfizer Investigational Site, Ahmedabad

560 001

Pfizer Investigational Site, Bangalore

682 026

Pfizer Investigational Site, Kochi

462 038

Pfizer Investigational Site, Bhopal

452 014

Pfizer Investigational Site, Indore

400 022

Pfizer Investigational Site, Mumbai

411 001

Pfizer Investigational Site, Pune

226 014

Pfizer Investigational Site, Lucknow

560 054

Pfizer Investigational Site, Bangalore

160 012

Pfizer Investigational Site, Chandigarh

641 014

Pfizer Investigational Site, Coimbatore

500 068

Pfizer Investigational Site, Hyderabad

Unknown

Pfizer Investigational Site, Hyderabad

226 003

Pfizer Investigational Site, Lucknow

141 001

Pfizer Investigational Site, Ludhiana

400 012

Pfizer Investigational Site, Mumbai